The Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend initiating iron therapy only for anemia-related indications, i.e., increasing hemoglobin (Hb) levels and minimizing the use of EPO-stimulating agents [3]. This evidence concerns the gene EPO and anemia.